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For improved tumor staging and therapy control, imaging biomarkers are of great interest allowing a noninvasive
characterization of invasiveness. In squamous epithelial skin and cervix lesions, transition to invasive stages is
associatedwith enhancedmatrixmetalloproteinase (MMP) activity, increased angiogenesis, andworsenedprognosis.
Thus, we investigated MMP activity as imaging biomarker of invasiveness and the potential of optical tomography in
characterizing the angiogenic and invasive behavior of skin squamous cell carcinoma (SCC) xenografts. MMP activity
wasmeasured in vivo in HaCaT-ras A-5RT3 tumors at different angiogenic and invasive stages (onset of angiogenesis,
intermediate and highly angiogenic, invasive stage) and after 1 week of sunitinib treatment by fluorescencemolecular
tomography–microcomputed tomography imaging using an activatable probe. Treatment response was additionally
assessedmorphologically by optical coherence tomography (OCT). In vivoMMPactivity significantly differed between
the groups, revealing highest levels in the highly angiogenic, invasive tumors that were confirmed by
immunohistochemistry. At the onset of angiogenesis with lowest MMP activity, fibroblasts were detected in the
MMP-positive areas, whereas macrophages were absent. Accumulation of both cell types occurred in both invasive
groups, again to a significantly higher degree at the most invasive and angiogenic stage. Sunitinib treatment
significantly reduced theMMP activity and accumulation of fibroblasts andmacrophages and blocked tumor invasion
that was additionally visualized by OCT. Human cervical SCCs also showed high MMP activity and a similar stromal
composition as the HaCaT xenografts, whereas normal tissue was negative. This study strongly suggests MMP
activity as imaging biomarker and demonstrates the high sensitivity of optical tomography in determining tumor
invasiveness that can morphologically be supported by OCT.
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In various tumor types including squamous cell carcinomas (SCCs),
the invasiveness correlates with tumor progression, metastasis, and a
poor clinical prognosis [1,2]. However, efficient therapy blocks tumor
invasion and reduces the invasiveness [3,4]. At present, the tumor
invasiveness is predominantly diagnosed on the basis of biopsies due
to the lack of adequate biomarkers that can be addressed
noninvasively. Hence, the noninvasive characterization of tumor
invasiveness is of great interest for tumor staging and therapy control.
Tumor invasion is crucially dependent on the action of proteases
such as matrix metalloproteinases (MMPs) that degrade various
components of the extracellular matrix (ECM), including constituents
of the basement membrane [5]. In addition to ECM degradation,
MMPs can alter cell-cell adhesion, thus promoting cell motility,
modulate the tumor immune response, and regulate angiogenesis and
metastasis [5,6]. MMPs are secreted by tumor and stromal cells [7]. In
the tumor stroma, major MMP expression that supports angiogenesis
and tumor invasion has been attributed to fibroblasts and macro-
phages [3,8,9]. In SCCs, enhanced MMP levels and activity are
observed at advanced, invasive tumor stages [3,7,8,10,11], suggesting
MMP activity as valuable biomarker for tumor invasiveness.
Fluorescence molecular tomography (FMT) allows noninvasive
quantitative tomographical imaging of fluorescent probes, and its
high sensitivity enables the use of molecular markers. In particular,
activatable probes have emerged as innovative tools for analyzing the
activity of proteases like MMPs in preclinical tumor models [12,13].
Different preclinical studies have been undertaken to apply optical
imaging of MMP activity for detecting early tumor stages ex vivo and
assessing therapy effects [14–17]. However, to the best of our
knowledge, near-infrared optical MMP imaging has not yet been
systematically analyzed with respect to its potential in characterizing
the angiogenic behavior and tumor invasiveness in vivo. Due to its
penetration depth of at least a few millimeters, it might also be
applicable for clinical tumors showing stepwise progression such as
squamous epithelial skin lesions that are located superficially or
squamous cervical tumors that can be reached endoscopically.
Because for both tumor types the surgical procedures and therapeutic
options are strongly dependent on the stage and the invasiveness of
the tumors, the noninvasive characterization of tumor invasiveness by
optical imaging can be of great value. In particular, that currently
conclusive diagnosis is achieved by invasive biopsy that is often
recurrently performed, as in the case of cervical lesions. Morpholog-
ically, tumor invasion can be detected by optical coherence
tomography (OCT), a noninvasive interferometric imaging technique
with growing importance in the clinical practice achieving near-
microscopic resolution [18,19].
Therefore, the aim of this study was to investigate in detail MMP
activity as in vivo biomarker of invasiveness and to assess the potential
of near-infrared FMT of MMP activity in characterizing the
invasiveness of HaCaT skin SCC xenografts. Because tumor invasion
is crucially dependent on angiogenesis and both processes are
substantially promoted by MMPs, the MMP activity was analyzed in
HaCaT SCC xenografts at the onset of angiogenesis, as well as in
intermediate and highly invasive and angiogenic SCCs. In addition,
the effects of the angiogenesis inhibitor sunitinib on MMP activity
and invasion were analyzed with respect to the potential of MMP
imaging in therapy monitoring. To additionally get morphologic
information of the tumor behavior, the tumor-stroma border was
analyzed ex vivo by OCT.Material and Methods
Tumor Inoculation
HaCaT-ras A-5RT3 SCC cells were cultured inDulbecco's modified
Eagle's medium, supplemented with 10% FBS, 1% penicillin (10000
U/ml), streptomycin (10,000 μg/ml), and 400 μg/ml geneticin G-418
sulphate (all from Gibco/Invitrogen, Carlsbad, CA USA). To obtain
HaCaT-ras A-5RT3 SCC tumor xenografts that differ in invasiveness
and angiogenic activity, tumors were induced by either subcutaneous
(s.c.) injection of 2 × 106 HaCaT-ras A-5RT3 cells in 100 μl of culture
medium or intradermal (i.d.) injection of 2 × 106 HaCaT-ras A-5RT3
cells in 30 μl of culture medium into the right flank of 6- to 8-week-old
female CD-1 nude mice (Charles River, Wilmington, MA USA) [11].
As additional tumor model, 5 × 106 MLS ovarian carcinoma cells
were injected s.c. in 100 μl of culture medium (minimum essential
medium; 10% FBS; Gibco/Invitrogen) into the right flank of 6- to
8-week-old female CD-1 nude mice (Charles River).
Study Design and Antiangiogenic Therapy
All experiments were approved by the Governmental Review
Committee on Animal Care. A total number of 26 animals were
included in the studies for the HaCaT-ras A-5RT3 model. The MMP
activity was analyzed in
i) early s.c. tumors at the onset of angiogenesis and invasion
(n = 7), 1 week after tumor inoculation,
ii) i.d. tumors (n = 5) representing an intermediate angiogenic
and invasive stage [20], 2 weeks tumor inoculation, and
iii) in s.c. advanced tumors (n = 5) of similar sizes as the i.d.
tumors (average tumor size: i.d. = 67 ± 19 mm3 i.d.; s.c. = 71 ±
22 mm3), 2 weeks after inoculation that represent a highly
angiogenic and invasive stage [6].
For the additional MLS ovarian carcinoma model, the s.c. tumors
were analyzed
i) at the onset of angiogenesis and invasion (n = 4), 1 week after
tumor inoculation and
ii) at the advanced stage (n = 4), 4 weeks after inoculation.
To analyze the effects of antiangiogenic therapy on the in vivo
MMP activity, HaCaT-rasA-5RT3–bearing mice (s.c. tumors, n = 5)
were treated with the clinically approved angiogenesis inhibitor
sunitinib (multispecific tyrosine kinase inhibitor). Treatment was
started after 1 week of tumor growth and continued for 1 week by
daily intraperitoneal injection of 40 mg/kg sunitinib (Pfizer, New
York City, NY USA). Untreated HaCaT-rasA-5RT3–bearing mice
(s.c. tumors, n = 4) of 2 weeks were used as controls.
Activated MMPs were measured in vivo through FMT–micro-
computed tomography (μCT) imaging using MMPSense 750 FAST
(PerkinElmer, Waltham, MA USA).
After the in vivo measurements, the animals were killed, and the
tumors were resected. For the therapy study, the tumor-stroma border
was additionally assessed ex vivo through OCT directly after killing. In
vivo and ex vivo data were validated by immunohistochemical analyses.
Clinical Samples
Frozen samples of invasive cervical SCC and adjacent healthy
cervical tissue were generously provided by the Department of
Pathology at University Hospital of Aachen (Aachen, Germany) in
accordance with the ethics committee.
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For assessing the MMP activity in vivo, MMPSense 750 FAST
(PerkinElmer) targeting a broad range of MMPs including MMP-2,
MMP-3, MMP-7, MMP-9, MMP-12, and MMP-13 was injected
i.v. into the mice through a tail vein catheter (2 nmol, total volume
of 100 μl per injection). MMP activity was measured 6 hours after
probe injection using an in vivo fluorescence tomograph (FMT 2500;
PerkinElmer) [21]. The mice were anesthetized with isoflurane during
imaging and fixed at a definite position in a dual-modality animal bed
(CT Imaging GmbH, Erlangen, Germany).
Microcomputed Tomography and Data Reconstruction
For organ and accurate signal localization, μCT was performed
directly before the FMT scan using a dual-energy μCT system
(Tomoscope Duo CT; CT Imaging GmbH). The mice were kept
anesthetized and fixed in the same animal bed for both μCT and
FMT. The following scan protocol was used: Both tubes were run at
65 kV and 0.38 mA. Each flat panel detector acquired 720
projections in the binned mode at 25 frames per second, containing
516 × 506 pixels with a pixel size of 100 μm. A full rotation with a
total scan time of 29 seconds was performed, and two subscans were
acquired, each covering 3 cm in the axial direction. After scanning, a
Feldkamp-type reconstruction was performed at isotropic voxel size of
(70 μm)3 using a ring artifact reduction method and a soft
reconstruction kernel.
Quantitative three-dimensional FMT data and volumetric μCT
data were fused using automated detection of markers as described in
Kunjachan et al [22]. MMPSense 750 FAST concentrations in the
tumors were determined using Amide's a Medical Imaging Data
Examiner (AMIDE) after having set regions of interest on the basis of
the anatomic μCT data [23,24].
Optical Coherence Tomography
Excised s.c tumors were scanned ex vivo in a dual-band OCT
system centered at 830 nm and 1220 nm. 2-dimensional (2D) OCT
images were taken from various planes within each tumor. The skin
covering the tumors was peeled off before scanning due to the high
scattering of the horn layer and to account for the restricted imaging
depth of the OCT (~1.5 mm). Clinically relevant OCT bandwidths
were chosen with 830 nm providing higher resolution (as used in
ophthalmology) and 1220 nm offering a higher penetration depth (as
used endoscopically) [18,25,26].
In situ Zymography and Indirect Immunofluorescence
Tumors were excised, scanned with OCT, afterwards deep frozen
at −80°C, and cut into 8-μm slices. The MMP activity was detected
in situ using a gelatinase assay (EnzCheck Gelatinase/Collagenase
Assay Kit; Invitrogen). Unfixed tumor sections were incubated with
the DQ substrate (Invitrogen, Carlsbad, CA USA) (40 μg/ml) for 30
minutes. After washing (3 × 10 minutes), the sections were fixed, and
subsequent immunofluorescence staining was performed as described
previously [27]. The following primary antibodies were applied: a
biotinylated antibody against smooth muscle actin (SMA) (α-SMA
biotin; Progen Pharmaceuticals [PROGEN Biotechnik GmbH,
Heidelberg, Germany]) to depict cancer-associated fibroblasts, an
antibody targeting F4/80-positive macrophages (anti-mouse F4/80
rat; AbD Serotec, Kidlington, UK), a CD31-specific antibody (anti-
mouse CD31 rat; BD Biosciences, San Jose, CA USA) for staining the
endothelium, an antibody against vascular endothelial growth factorreceptor 2 (VEGFR2) (anti-mouse VEGFR2 goat; R&D Systems,
Minneapolis, MN USA) for analyzing the angiogenic activity, and an
antibody against keratins [anti-human pan keratin (PK) guinea pig;
Progen Pharmaceuticals] for staining the tumor cells. Corresponding
secondary antibodies were used as previously described [27]. Cell
nuclei were counterstained by 49,6-diamidino-2-phenylindole
(DAPI; Invitrogen).
For human samples, anti-human CD31 (anti-human CD31
rabbit; Acris Antibodies GmBH, Herford, Germany), anti-
VEGFR2 (anti-human VEGFR2 mouse, Dianova, Hamburg,
Herford, Germany), and anti-CD68 (anti-human CD68 rat, against
macrophages, AbD Serotec, Kidlington, UK) antibodies were used.
Staining was done as described [27].
Stained sections were examined and photographed with the Carl
Zeiss Axio Imager M2 (Carl Zeiss, Jena, Germany). Images were
quantified by determining the percentage of immunofluorescent
positive area fractions. For each tumor, four to seven micrographs
including the top, bottom, both sides, and the center were analyzed
using the AxioVision Rel 4.8 software (Carl Zeiss).
Statistics
A two-tailed Student's t test was applied for statistical analysis
using Excel (Microsoft, Redmond, WA USA). A P value of less
than .05 was considered as statistically significant, a P value of
less than .01 as highly significant, and a P value of less than .001 as
very highly significant.
Results
MMP Activity as Imaging Biomarker of the Angiogenic Status
and Invasiveness of HaCaT SCC Xenografts
Because enhanced MMP expression and activity are associated with
angiogenesis, tumor progression, and invasion in different tumor
types including SCCs, we investigated MMP activity as biomarker of
invasiveness and the potential of in vivo MMP imaging in the
noninvasive characterization of tumor invasiveness and the angiogenic
activity. We used the HaCaT-ras A-5RT3 SCC model because it had
been well characterized in a previous study [11] for the in vivo
expression of MMP-2, MMP-3, MMP-9, and MMP-13 that are
targeted by the near-infrared probe MMPSense 750 FAST. Enhanced
expression and activity of these MMPs have been observed in various
tumors including SCCs [6,10]. The MMP activity was therefore
measured in vivo by FMT-μCT imaging and compared in HaCaT-
ras A-5RT3 SCC xenografts at different stages of angiogenesis and
invasiveness, in s.c. tumors at the onset of angiogenesis and invasion,
in i.d. tumors representing an intermediate angiogenic and invasive
stage, and in s.c. advanced, highly angiogenic, and invasive tumors
(Figure 1, A–C).
The in vivo MMP activity significantly differed between the
groups. Highest levels were measured in the advanced, highly
angiogenic, and invasive s.c. HaCaT-ras A-5RT3 tumors, followed by
the i.d. tumors at the intermediate stage, whereas lowest activity was
recorded for s.c. tumors at the onset of angiogenesis and invasion
(Figure 2, A and C). This was confirmed ex vivo on tumor sections by
in situ zymography (Figure 2, B and D).
In the tumor microenvironment, fibroblasts and macrophages have
been identified as strong MMP-expressing cells that promote
angiogenesis and tumor invasion [3]. We therefore analyzed the
presence of SMA-positive fibroblasts and F4/80-positive macrophages
in the HaCaT-ras A-5RT3 tumors at differential angiogenic and
Figure 1. HaCaT-ras A-5RT3 variants represent different angiogenic and invasive stages. Quantification (A and B) of immunostainings for
CD31 and VEGFR2 (C) shows the highest vessel density (A and C), angiogenic activity (B and C), and invasiveness (C) in s.c. advanced
tumors (n = 5), whereas i.d. tumors (n = 5) have an intermediate angiogenic and invasive stage, and s.c. early tumors are at the onset of
angiogenesis and invasion (n = 7). (C) Representative immunostainings of the different HaCaT-ras A-5RT3 variants for CD31 (green),
VEGFR2 (red), DAPI (blue), or PK (blue), respectively. Right panels (bar, 50 μm) are magnified selected areas of the left panels (bar, 200 μm)
(indicated by the red square). Data are presented as means ± SD (*P b .05 and ***P b .001).
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were significantly higher in advanced s.c. than in i.d. (P b .01 for
both) and early s.c. tumors (P b .001 for both), demonstrating the
strongest presence of fibroblasts and macrophages in the tumors with
highest angiogenic activity and strongest invasiveness (Figure 3, A
and B; representative immunostainings are shown in Figure 3C).
Interestingly, whereas SMA-positive fibroblasts were observed in early
s.c. tumors at the onset of angiogenesis, even in vessel-free areas, no
macrophages were detected at this stage.
To expand the application and to further analyze the sensitivity
of in vivo MMP imaging in determining the invasiveness and
angiogenic activity of tumors, MMP activity was additionally
measured in vivo in s.c. ovarian carcinoma xenografts (MLS) at an
early (1 week post-injection) and advanced stages (4 weeks post-
injection) by FMT-μCT imaging. Comparably to the HaCaT-ras
A-5RT3 tumors, MMP activity in vivo and ex vivo also significantly
differed between the differential stages in the MLS tumors,
confirming the sensitivity of in vivo MMP imaging and the
suitability of MMP activity as imaging biomarker of invasiveness
and angiogenesis (Figure W1).
Optical Tomography of MMP activity Accurately Depicts the
Reduced Angiogenesis and Invasion After Antiangiogenic
Treatment with Sunitinib
MMPs are crucially involved in angiogenesis, and MMP activity
has been shown to correlate with the degree of angiogenesis andtumor invasion in the HaCaT-ras A-5RT3 xenografts. Previous
work on differentially aggressive HaCaT xenografts had demon-
strated that VEGFR2 blockade by DC101 strongly reduced MMP
expression and activity and resulted in reversion to a premalignant
noninvasive tumor phenotype [28,29]. We therefore investigated
the effects of the strong angiogenesis inhibitor sunitinib on
angiogenesis and invasion and whether MMP imaging could
also depict the effects of the therapy on tumor angiogenesis and
invasion. To this end, tumor-bearing mice were treated for 1 week
with sunitinib after 1 week of tumor growth, and the MMP activity
was compared with 2-week-old highly angiogenic and invasive
untreated controls.
Sunitinib treatment resulted in a significantly lower microvessel
density and angiogenic activity compared with untreated controls
(Figure 4, A and B, representative immunostainings are shown in
Figure 4C; P b .001 for both). In addition, tumor invasion was
inhibited in the sunitinib-treated mice, where the tumors appeared
encapsulated with regular borders and necrotic areas in the center
(Figures 4C and 5D).
Optical tomography revealed a significantly lower in vivo MMP
activity in sunitinib-treated mice compared with the untreated
controls (Figure 5A; P b 0.001; representative images shown in
Figure 5C). In agreement with the in vivo data, a significantly
decreased MMP activity was detected ex vivo on the sections of the
treated tumors compared with the controls (Figure 5B; P b .01;
representative immunostainings are shown in Figure 5D).
Figure 2. MMP activity differs significantly between the HaCaT-A-5RT3 tumors at differential angiogenic and invasive stages.
(A) Assessment of MMP activity in vivo by FMT-μCT imaging reveals significant differences in intratumoral concentrations of activated
MMPSense 750 FAST between s.c. advanced (n = 5), i.d. intermediate (n = 5), and s.c. early (n = 7) tumors. Highest concentrations are
recorded for s.c. advanced tumors at the highly angiogenic and invasive stage, whereas lowest concentrations are found in s.c. early tumors
at the onset of angiogenesis and invasion. (B) Quantification of in situ zymography of MMP activity on tumor sections confirms the in vivo
data. (C) Representative FMT/μCT fusion images of tumor-bearing mice (transverse plane) show the fluorescent signals of activated
MMPSense 750 FAST in s.c. early, i.d., and s.c. advanced tumors (tumors indicated by a white arrow). The additional fluorescent signals
found in the intestine region can occur from hepatobiliary excretion of the probe through the intestine. (D) Representative images of
in situ zymography of MMP activity (green) [counterstained with collagen IV (red) and DAPI (blue)] of an s.c. early-stage tumor at the
onset of angiogenesis and invasion, an i.d. tumor at the intermediate angiogenic and invasion stage, and an s.c. advanced, highly
angiogenic, and invasive tumor. (E) Representative H&E staining of the different HaCaT-ras A-5RT3 tumors. Bar, 200 μm. Data are presented
as means ± SD (*P b .05, ** P b .01, and ***P b .001).
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macrophages, the amount of both cell types was significantly reduced
in the sunitinib-treated tumors compared with the untreated controls,
as shown by the significantly lower SMA- and F4/80-positive area
fractions, respectively (Figure 6, A and B; P b .001 for fibroblasts and
P b .01 for macrophages; representative immunostainings are shown
in Figure 6C ).OCT Depicts Reduced Tumor Invasion After Sunitinib
Treatment
To further characterize the tumor invasion at a morphologic level,
the tumors were scanned ex vivo using a dual-band OCT system. An
irregular tumor border zone was detected in the untreated 2-week-old
s.c. HaCaT-ras A-5RT3 tumors (Figure 7A). In contrast, the
sunitinib-treated tumors were clearly separated from the upper
Figure 3. Quantification of SMA-positive fibroblasts (A) and F4/80-positivemacrophages (B) shows a differential accumulation at the distinct
stages of angiogenesis and invasion. Highest accumulation of these cells is found in s.c. advanced tumors at the highest angiogenic and
invasive stage. Notably, no macrophages are detected in the s.c. early tumors at the onset of angiogenesis and invasion. (C) Representative
immunostainings for SMA (red), F4/80 (green), andDAPI (blue) of an s.c. early tumor at the onset of angiogenesis, an i.d. tumor at intermediate
stage of angiogenesis and invasion, and an s.c. advanced, highly angiogenic, and invasive tumor. Bar, 100 μm.Data are presented asmeans±
SD (**P b .01 and ***P b .001; s.c. early: n = 7, i.d. intermediate: n = 5, and s.c. advanced: n = 5).
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zation of the tumor border zone (Figure 7B). Immunohistochemical
analysis of the corresponding tumor sections confirmed the irregular
tumor border in the untreated tumors with invasive, infiltrating
tumor protrusions (Figure 7C), whereas invasion was blocked by
sunitinib treatment, and the border of the encapsulated tumors was
well demarcated and partially collagen IV positive (Figure 7D). TheseFigure 4. Sunitinib treatment results in strong reduction of angiogenesis
of immunostainings for CD31 andVEGFR2demonstrates the significan
treated tumors (n=5) comparedwith untreated controls (n=4). (C) Rep
(PK; blue), or DAPI (blue), respectively, of an untreated control and sun
areas of the left panels (bar, 200 μm) (indicted by a red square). Data adata demonstrate that OCT allows the morphologic characterization
of the tumor behavior at a high resolution (Figure 7).
MMP Activity and Stromal Composition of Clinical SCCs are
Similar to the HaCaT SCC Xenografts
To analyze whether MMP activity is also a biomarker of invasiveness
in clinical SCCs, we analyzed theMMP activity in invasive cervical SCCand blocks invasion of s.c. HaCaT-rasA-5RT3 tumors. Quantification
t reduction in vessel density (A) and angiogenic activity (B) in sunitinib-
resentative immunostainings for CD31 (green), VEGFR2 (red), keratin
itinib-treated tumor. Right panels (bar, 50 μm) are magnified selected
re presented as means ± SD. (***P b .001).
Figure 5. Sunitinib treatment significantly reduces MMP activity in HaCaT-rasA-5RT3 tumors. (A) Assessment of MMP activity in vivo by FMT/
μCT hybrid imaging demonstrates significantly decreased concentrations of activatedMMPSense 750 FAST in sunitinib-treated tumors (***P b
.001;n=5) comparedwith untreated controls (n=4). (B)Quantification of in situ zymographyofMMPactivity on tumor sections confirms again
the in vivo results. (C) Representative FMT/μCT fusion imagesof tumor-bearingmice (transverseplane) show the fluorescent signals of activated
MMPSense 750 FAST in an untreated control and sunitinib-treated tumor (tumors indicated by a white arrow). (D) Representative images of in
situ zymography of MMP activity (green) counterstained with collagen IV (red) and DAPI (blue) of an untreated control and sunitinib-treated
tumor. (E) RepresentativeH&Estainingof thedifferentHaCaT-rasA-5RT3 tumors.Bar, 200μm.Data arepresentedasmeans±SD (**Pb .01 and
***P b .001).
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Whereas noMMP activity was found in normal cervical tissue, a strong
MMP activity was detected in stromal strands of cervical SCC samples,
showing similarities to the advanced s.c. highly invasive HaCaT-ras
A-5RT3 tumors (Figure 8, A and B). Strong eosin-positive, collagen-
enriched strands were detected in the invasive tumor areas of the SCCs,
whereas no ECM-enriched areas were found in normal cervical samples
by hematoxylin and eosin (H&E) staining (Figure 8, C and D).
Moreover, a strong infiltration of SMA-positive fibroblasts and
macrophages was detected in the cervical SCCs, whereas SMA-positive
fibroblasts were absent in the normal cervical tissue, and the amount of
macrophages was markedly lower (Figure 8, E and F). This confirmedthe strong up-regulation of MMP activity in invasive cervical human
SCCs compared with healthy cervical tissue (Figure 8A) and a similar
stromal composition as in the HaCaT-ras A-5RT3 SCC xenografts.
Discussion
In tumors that develop stepwise such as SCCs of the skin and the
cervix, the invasiveness correlates with tumor progression, metastasis,
and a worse clinical prognosis and is predominantly diagnosed by
invasive biopsies [1–4]. In addition, surgical and therapeutic
strategies in these tumors depend on the tumor stage. Hence,
distinct imaging biomarkers that allow a noninvasive characteriza-
tion of tumor invasion are of great interest for improving tumor
Figure 6. Quantification of SMA-positive fibroblasts (A) and F4/80-positive macrophages (B) shows the significantly reduced
accumulation of both cell types in sunitinib-treated s.c. HaCaT-rasA-5RT3 tumors compared with the untreated controls. (C)
Representative immunostainings for SMA (red), F4/80 (green), and DAPI (blue) of an untreated control and a sunitinib-treated tumor. Bar,
100 μm. Data are presented as means ± SD (**P b .01 and ***P b .001; untreated controls: n = 4; sunitinib-treated tumors: n = 5).
Figure 7. OCT depicts the blockade of invasion after sunitinib treatment at the morphologic level. Morphologic characterization of the
tumor border by dual-band OCT clearly shows the blockade of invasion after treatment of HaCaT-rasA-5RT3–bearing mice with sunitinib.
OCT images (800 and 1220 nm, respectively) of an untreated control (A) and a sunitinib-treated tumor (B). Note the irregular tumor border
(indicated by a yellow arrow), typical characteristics of invasion of the untreated control (A), whereas the tumor is separated from the
upper dermis by a regular line in the sunitinib-treated tumor (B, indicated by a yellow arrow). (C and D) In situ zymography of MMP activity
and counterstaining for collagen IV (red) and DAPI (blue) on corresponding tumor sections demonstrate the irregular tumor border with
invasive, infiltrating tumor cell protrusions (indicated by a yellow arrow) in the untreated control tumor (C). In contrast, tumor invasion is
blocked after sunitinib treatment, and the tumor is encapsulated and well demarcated from the stroma (D). Note also the partial
deposition of collagen IV deposition at the border (indicated by a yellow arrow) and the necrotic area in the center (indicated by a yellow
N). (E and F) Representative H&E staining of the different HaCaT-ras A-5RT3 tumors. OCT image size: 2.5 * 1.6 mm. Bar, 200 μm.
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Figure 8. Human cervical SCC samples show also a highMMP activity and a similar stroma composition as the HaCaT-SCC xenografts. In situ
zymographyofMMPactivity (green) andcounterstaining for collagen IV (red) andDAPI (blue) of humansamples reveals the strongMMPactivity
in the invasive cervical SCC (A), whereas the healthy tissue is negative (B). H&E staining demonstrates strong eosin-positive, collagen-enriched
stromal strands in the cervical SCC (C) that resemble the strands seen in the s.c. advancedhighly invasiveHaCaT-rasA-5RT3 tumors,whereas in
the healthy cervical tissue (D), no ECM-enriched areas are obvious. (E–G) Immunostaining for SMA-positive fibroblasts and CD68-positive
macrophages shows the strong infiltration of these cell types in the cervical SSC (E and G), whereas SMA-positive fibroblasts are absent in
healthy cervical tissue, and markedly fewer macrophages are detected (F and H). SMA (green), CD68 (red), and DAPI (blue). Bar, 200 μm.
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identified as key players in promoting tumor cell invasion and
dissemination, and enhanced activity is usually found at invasive,
advanced tumor stages and associated with a poor clinical prognosis[1,2,30,31]. In addition, MMPs regulate angiogenesis, a crucial
process promoting sustained tumor growth, dissemination, and
metastasis [32,33]. However, MMPs are downregulated in response
to cancer therapies, including efficient antiangiogenic therapy [8,29].
244 MMP Activity as an Imaging Marker of Invasiveness Al Rawashdeh et al. Neoplasia Vol. 16, No. 3, 2014This suggests that the MMP activity might be a promising imaging
biomarker for noninvasive tumor staging and therapy control. In this
context, optical imaging of MMP activity using biocompatible near-
infrared fluorogenic MMP substrates as activatable reporter probes
has been established for about a decade as innovative technique and
allows a sensitive detection of MMP activity in vivo [14,34,35].
Moreover, hybrid imaging allows unambiguous association of
fluorescent signal to the respective organs, increasing the reproduc-
ibility of the analysis [22].
Thus, the aim of our study was to investigate MMP activity as an
in vivo biomarker of tumor invasiveness and angiogenesis and to assess
the potential of noninvasive optical tomography of MMP activity in
characterizing skin SCC xenografts that differ in invasiveness and
angiogenic activity. In addition, MMP imaging was assessed with
respect to monitoring of antiangiogenic therapy by sunitinib. Analysis
was done in the HaCaT-ras A-5RT3 model that had been well
characterized in a previous study [11] with regard to in vivo
expression of MMP-2, MMP-3, MMP-9, and MMP-13 that are
targeted by the probe MMPSense 750 FAST.
To this end, the MMP activity was measured in vivo in early s.c.
HaCaT-ras A-5RT3 tumors at the onset of angiogenesis and invasion
(1 week post-injection) in advanced highly invasive and angiogenic s.
c. tumors (around 2 weeks post-injection) and in i.d. injected
HaCaT-ras A-5RT3 tumors (around 2 weeks post-injection) of a
similar size as the advanced s.c. tumors representing an intermediate
invasive and angiogenic stage. Optical tomography of MMP activity
sensitively discriminated between the xenografts at different invasive
and angiogenic stages, revealing significant differences in the activity
between all groups. Highest in vivo activity was measured in the
advanced, highly angiogenic, and invasive s.c. HaCaT-ras A-5RT3
tumors, whereas lowest activity was recorded for the early s.c. tumors
at the onset of angiogenesis. This was confirmed ex vivo on tumor
sections by in situ zymography, demonstrating the high accuracy of
in vivo MMP imaging. The results strongly suggest that MMP
activity is a useful imaging marker of SCC invasiveness. Previous
studies performed by other groups have already demonstrated that
near-infrared imaging of MMP activity has a high sensitivity and
accuracy in detecting early colon tumor stages ex vivo [16,17].
However, we here provide evidence of the high sensitivity and
accuracy of near-infrared optical tomography for discriminating
differential stages of tumor angiogenesis and invasiveness in living
mice in vivo. Additional analysis of a s.c. ovarian carcinoma xenograft
model at differential stages of angiogenesis and invasiveness also
revealed significant differences in the in vivo MMP activity
comparably to the HaCaT-ras A-5RT3 xenografts, thus confirming
the sensitivity of in vivo MMP imaging and the suitability of MMP
activity as imaging biomarker of invasiveness and angiogenesis.
Further immunohistochemical analyses of the tumor sections
revealed the strongest accumulation of SMA-positive fibroblasts and
F4/80-positive macrophages in s.c. advanced, highly angiogenic, and
invasive tumors, being also significantly higher than in i.d. tumors at
the intermediate stage. Both fibroblasts and macrophages have been
demonstrated to promote angiogenesis, tumor invasion, and
progression by secreting cytokines (e.g., VEGF), chemokines, and
MMPs [7,8]. Thus, the significantly enhanced accumulation of
these cell types can explain the highest MMP activity as well as the
strongest angiogenesis and invasiveness of the advanced s.c. tumors.
Interestingly, no macrophages were detected in early s.c. tumors at
the onset of angiogenesis and invasion, whereas SMA-positivefibroblasts were present within the intratumoral stromal strands,
even in vessel-free areas. These findings are in line with our previous
studies on skin SCCs showing that fibroblasts crucially promote
angiogenesis by expression of cytokines and MMPs like MMP-13
[7,27]. The delayed infiltration of macrophages at stages with
enhanced vascularization suggests that they are predominantly
recruited through the bloodstream, probably also triggered by
cytokine induction in fibroblasts [3]. This further suggests that
initial growth and invasion of these tumors are promoted by
fibroblasts, whereas inflammation additionally maintains angiogen-
esis and invasion at advanced stages [36].
Previous studies in differentially aggressive HaCaT SCC xenografts
had revealed that antiangiogenic therapy with DC101 revert the
tumor phenotype to a premalignant noninvasive stage, accompanied
by a strong reduction in MMP expression and activity [28,29]. We
therefore investigated the MMP activity as in vivo biomarker for
therapy control and whether MMP imaging can depict the effects of
antiangiogenic therapy on tumor invasion. Sunitinib, a clinically used
US Food and Drug Administration (FDA)-approved multispecific
tyrosine kinase inhibitor, was used due to its known strong
antiangiogenic effects [37].
As expected, treatment of HaCaT-rasA-5RT3–bearing mice for
1 week with sunitinib resulted in a significantly reduced
angiogenesis and microvessel density compared with the untreated
controls. In addition, antiangiogenic therapy blocked tumor
invasion, resulting in encapsulated tumors with necrotic areas in
the center that were well demarcated from the stroma and at the
border partially positive for the basement membrane component
collagen IV. In line with the reduced invasiveness, optical
tomography demonstrated a significantly lower MMP activity in
the sunitinib-treated tumor-bearing mice in vivo, being again
confirmed ex vivo. Further immunohistochemical analyses revealed
a significantly lower accumulation of fibroblasts and macrophages
after sunitinib treatment. Although antiangiogenic therapy has
previously been shown to almost abrogate the infiltration of SMA-
positive fibroblasts in tumor-bearing mice [29], we believe that
reduced macrophage accumulation occurred as a consequence of
blood vessel regression, thus impairing the recruitment of mono-
cytes from the blood circulation. This demonstrates that
antiangiogenic therapy efficiently reduced the MMP activity,
“normalized” the stroma, and inhibited tumor invasion. Further-
more, MMP activity has been shown as a suitable imaging
biomarker for monitoring inhibition of tumor invasion in response
to efficient antiangiogenic therapy.
To further analyze the effects of antiangiogenic therapy at the
morphologic level, the excised tumors were analyzed ex vivo by dual-
band OCT. The OCT system covers two clinically relevant
bandwidths centered at 830 nm and 1220 nm, providing higher
image resolution at 830 nm and a higher penetration depth at 1220
nm, respectively [18,25,26]. Whereas an irregular tumor border zone
was detected in the untreated s.c. HaCaT-ras A-5RT3 tumors, typical
morphologic characteristics of invasive tumors, the tumor was clearly
demarcated from the mouse stroma by a regular precise line after
sunitinib treatment. Immunohistochemical analyses of corresponding
tumor sections confirmed the irregular tumor stroma border in the
untreated controls with invasive, infiltrating tumor areas and the
regular borders of the encapsulated tumor after sunitinib treatment.
These data further highlight the potential of OCT in the noninvasive
morphologic characterization of tumors at high resolution.
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of tumor invasiveness in clinical SCCs, cervical SCC and adjacent
healthy cervix tissues were analyzed by in situ zymography. A high
MMP activity was detected within stromal strands in the invasive
areas of the cervical cancer samples, closely resembling those found in
advanced s.c. HaCaT-ras A-5RT3 tumors. In contrast, no MMP
activity was detected in healthy cervical tissue. In addition, a
pronounced stromal infiltrate of SMA-positive fibroblasts and
macrophages was found in invasive cervical carcinomas, closely
resembling the stromal composition of the HaCaT xenografts.
These findings support the hypothesis that MMP activity is a useful
imaging marker of SCC invasiveness. Because skin and cervical
carcinoma development involves typical progression stages (dysplasia,
carcinoma in situ, and invasive carcinoma) and MMP up-regulation is
associated with transition to the invasive stage [2,38-40], our results
suggest that near-infrared imaging of MMP activity might have
potential in the noninvasive staging of squamous skin lesions that are
located superficially or cervical lesions that can be reached endoscop-
ically. A more profound noninvasive characterization of these lesions by
molecular MMP imaging additionally to white light illumination for
detection might be of great value because both the surgical and
therapeutic interventions in these tumor entities strongly depend on the
tumor stage [41,42]. However, whether MMP imaging might be
feasible in the clinic for initial detection of lesions needs further
investigation. A first in vivo endoscopic approach of detecting active
proteases by near-infrared imaging with potential for clinical translation
has been undertaken by Alencar et al. [43]. They used a modified near-
infrared imaging microcatheter, combining white light and fluores-
cence, with a protease-activatable probe, cathepsin B, that allowed a
sensitive early detection of colon tumors in mice in vivo, which might
potentially decrease themiss rate of neoplastic colon lesions and increase
the speed of colonic examinations [43].
In light of the recent developments, the results of the study further
suggest that a combination of near-infrared optical imaging and OCT
might be beneficial for obtaining noninvasive information of bothMMP
activity and morphologic characteristics to improve staging or therapy
control of cancers such as cervical or skin SCCs. Future applications of
combined imaging are suggested as optical biopsies for superficial skin
tumors or endoscopic/ laparoscopic applications in cervical lesions,
including guidance and assistance in intraoperative surgery.
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